290 Chapter 12 REFERENCES [1] van Gestel, Y.R.; Thomassen, I.; Lemmens, V.E.; Pruijt, J.F.; van Herk-Sukel, M.P.; Rutten, H.J.; Creemers, G.J.; de Hingh, I.H. Metachronous peritoneal carcinomatosis after curative treatment of colorectal cancer. Eur. J. Surg. Oncol. 2014, 40, 963–969. https://doi.org/10.1016/j. ejso.2013.10.001. [2] Simkens, G.A.; Wintjens, A.; Rovers, K.P.; Nienhuijs, S.W.; de Hingh, I.H. Effective Strategies to Predict Survival of Colorectal Peritoneal Metastases Patients Eligible for Cytoreductive Surgery and HIPEC. Cancer Manag. Res. 2021, 13, 5239–5249. https://doi.org/10.2147/cmar. S277912. [3] Lurvink, R.J.; Bakkers, C.; Rijken, A.; van Erning, F.N.; Nienhuijs, S.W.; Burger, J.W.; Creemers, G.J.; Verhoef, C.; Lemmens, V.E.; De Hingh, I.H. Increase in the incidence of synchronous and metachronous peritoneal metastases in patients with colorectal cancer: A nationwide study. Eur. J. Surg. Oncol. 2021, 47, 1026–1033. https://doi.org/10.1016/j.ejso.2020.11.135. [4] Koppe, M.J.; Boerman, O.C.; Oyen, W.J.; Bleichrodt, R.P. Peritoneal carcinomatosis of colorectal origin: Incidence and current treatment strategies. Ann. Surg. 2006, 243, 212–222. https:// doi.org/10.1097/01.sla.0000197702.46394.16. [5] Klaver, Y.L.; Lemmens, V.E.; Nienhuijs, S.W.; Luyer, M.D.; de Hingh, I.H. Peritoneal carcinomatosis of colorectal origin: Incidence, prognosis and treatment options. World J. Gastroenterol. 2012, 18, 5489–5494. https://doi.org/10.3748/ wjg.v18.i39.5489. [6] Kranenburg, O.; van der Speeten, K.; de Hingh, I. Peritoneal Metastases from Colorectal Cancer: Defining and Addressing the Challenges. Front. Oncol. 2021, 11, 650098. https://doi. org/10.3389/fonc.2021.650098. [7] Kamiyama, H.; Noda, H.; Konishi, F.; Rikiyama, T. Molecular biomarkers for the detection of metastatic colorectal cancer cells. World J. Gastroenterol. 2014, 20, 8928–8938. https:// doi.org/10.3748/wjg.v20.i27.8928. [8] Sadahiro, S.; Suzuki, T.; Ishikawa, K.; Nakamura, T.; Tanaka, Y.; Masuda, T.; Mukoyama, S.; Yasuda, S.; Tajima, T.; Makuuchi, H.; et al. Recurrence patterns after curative resection of colorectal cancer in patients followed for a minimum of ten years. Hepatogastroenterology 2003, 50, 1362–1366. [9] Maggiori, L.; Elias, D. Curative treatment of colorectal peritoneal carcinomatosis: Current status and future trends. Eur. J. Surg. Oncol. 2010, 36, 599–603. https://doi.org/10.1016/j. ejso.2010.05.007. [10] Jayne, D.G.; Fook, S.; Loi, C.; Seow-Choen, F. Peritoneal carcinomatosis from colorectal cancer. Br. J. Surg. 2002, 89, 1545–1550. https:// doi.org/10.1046/j.1365-2168.2002.02274.x. [11] Quénet, F.; Elias, D.; Roca, L.; Goéré, D.; Ghouti, L.; Pocard, M.; Facy, O.; Arvieux, C.; Lorimier, G.; Pezet, D.; et al. Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy versus cytoreductive surgery alone for colorectal peritoneal metastases (PRODIGE 7): A multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2021, 22, 256–266. https:// doi.org/10.1016/s1470-2045(20)30599-4. [12] Bakkers, C.; Lurvink, R.J.; Rijken, A.; Nienhuijs, S.W.; Kok, N.F.; Creemers, G.J.; Verhoef, C.; Lemmens, V.E.; van Erning, F.N.; De Hingh, I.H. Treatment Strategies and Prognosis of Patients with Synchronous or Metachronous Colorectal Peritoneal Metastases: A Population-Based Study. Ann. Surg. Oncol. 2021, 28, 9073–9083. https://doi.org/10.1245/s10434-021-10190-z. [13] Xue, L.; Hyman, N.H.; Turaga, K.K.; Eng, O.S. Peritoneal Metastases in Colorectal Cancer: Biology and Barriers. J. Gastrointest. Surg. 2020, 24, 720–727. https://doi.org/10.1007/s11605019-04441-4. [14] Sorich, M.J.; Wiese, M.D.; Rowland, A.; Kichenadasse, G.; McKinnon, R.A.; Karapetis, C.S. Extended RAS mutations and anti-EGFR monoclonal antibody survival benefit in metastatic colorectal cancer: A meta-analysis of randomized, controlled trials. Ann. Oncol. 2015, 26, 13–21. https://doi.org/10.1093/annonc/ mdu378. [15] Taniguchi, H.; Uehara, K.; Nakayama, G.; Nakayama, H.; Aiba, T.; Hattori, N.; Kataoka, M.; Nakano, Y.; Kawase, Y.; Okochi, O.; et al. Tumor Location Is Associated with the Prevalence of Braf And Pik3ca Mutations in Patients with Wild-Type Ras Colorectal Cancer: A Prospective Multi-Center Cohort Study in Japan. Transl. Oncol. 2020, 13, 100786. https://doi. org/10.1016/j.tranon.2020.100786. [16] Graf, W.; Cashin, P.H.; Ghanipour, L.; Enblad, M.; Botling, J.; Terman, A.; Birgisson, H. Prognostic Impact of BRAF and KRAS Mutation in Patients with Colorectal and Appendiceal Peritoneal Metastases Scheduled for CRS and HIPEC. Ann. Surg. Oncol. 2020, 27, 293–300. https://doi. org/10.1245/s10434-019-07452-2.
RkJQdWJsaXNoZXIy MTk4NDMw